Perseus Proteomics Co-authors Breakthrough ANKL Therapy Paper

Perseus Proteomics, Inc. (JP:4882) has released an update.

Perseus Proteomics Inc., in collaboration with Osaka University, has published a paper in the journal ‘Leukemia’ detailing the potential of using LAT1 as a biomarker to predict the effectiveness of their ANKL therapy, PPMX-T003. The research is part of ongoing efforts to develop treatments for blood diseases, including ANKL, which is a rare and difficult-to-treat condition. A phase I/II clinical trial is currently in progress to further investigate the therapeutic potential of PPMX-T003.

For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.